ストックスクリーナーアプリを入手
58.99
1.37%
-0.815
前日終値:
$59.81
開ける：
$60.21
24時間の取引高:
2.41M
Relative Volume:
0.34
時価総額：
$23.43B
収益：
$2.23B
当期純損益:
$-3.19B
株価収益率:
-7.242
EPS:
-8.1462
ネットキャッシュフロー:
$-1.60B
1週間 パフォーマンス:
+3.51%
1か月 パフォーマンス:
-13.59%
6か月 パフォーマンス:
+45.62%
1年 パフォーマンス:
+131.61%
1日の値動き範囲:
$58.60
$61.40
1週間の範囲:
$53.71
$61.40
52週間の値動き範囲:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Compare MRNA vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
59.04 | 22.07B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
530.82 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.27 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
863.60 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.21 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
363.48 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Equal Weight |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-12 | 開始されました | Jefferies | Hold |
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
Eversept Partners LP Has $8.11 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Renaissance Technologies LLC Acquires 312,800 Shares of Moderna, Inc. $MRNA - MarketBeat
(MRNA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Moderna (MRNA) Laps the Stock Market: Here's Why - Yahoo Finance Singapore
After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy? - The Globe and Mail
After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy? - The Motley Fool
Therapeutics Stocks Q1 Highlights: Moderna (NASDAQ:MRNA) - Yahoo Finance
Weiss Asset Management LP Has $4.76 Million Position in Moderna, Inc. $MRNA - MarketBeat
Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Moderna stock stays tied to vaccine demand and cash burn - Ad-hoc-news.de
Moderna, Inc. Revenue Breakdown – BX:0QF - TradingView
Moderna Inc (MRNA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Moderna: A Stock to Watch or a Risky Bet? - The Globe and Mail
Moderna Inc (MRNA) Institutional Confidence - TradingKey
Moderna Inc (MRNA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Moderna, Inc. Revenue Breakdown – VIE:MRNA - TradingView
Moderna stock may move 4.2% on July 31 earnings release By Investing.com - Investing.com Nigeria
Moderna stock may move 4.2% on July 31 earnings release - Investing.com
Moderna Inc (MRNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Baillie Gifford (MRNA) discloses 18.2M Moderna shares in latest 13G/A - Stock Titan
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance Singapore
Moderna (MRNA) Stock Looks Above Fair Value After Cancer Trial News - simplywall.st
First Trust Advisors LP Raises Stock Position in Moderna, Inc. $MRNA - MarketBeat
GC Biopharma Files for Phase 2 Trial of Korean-Made mRNA COVID-19 Vaccine, Aiming for August Start - finance.biggo.com
Moderna Inc (MRNA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Moderna (MRNA) Projected to Post Earnings on Friday - MarketBeat
Earnings Preview: What To Expect From Moderna’s Report - Yahoo Finance
Biotech experts want FDA drug reviews based on science, not politics - marketscreener.com
Himension Capital Singapore PTE. LTD. Cuts Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Rabies Vaccine Candidate by Moderna Inc.mRNA approach in early trials - AD HOC NEWS
Bank of New York Mellon Corp Reduces Position in Moderna, Inc. $MRNA - MarketBeat
California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA - MarketBeat
Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near? - Yahoo! Finance Canada
Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift - Yahoo Finance
The mRESV by Moderna. An mRNA RSV vaccine candidate for older adults - Ad-hoc-news.de
Moderna stock stabilizes as oncology pipeline and vaccine revenue reshape growth outlook - Ad-hoc-news.de
MRNA Maintained and Target Raised by Goldman Sachs -- Now $67.00 - GuruFocus
Moderna stock outlook: doubled YTD but Wall Street says the easy money is made - Investing.com
Moderna Inc. Stock Slides 3.8%, Underperforms Peers - webull.com
Moderna, Inc. $MRNA Stock Holdings Increased by Fifth Third Bancorp - MarketBeat
Moderna Hits CureVac With Countersuit In COVID Vax Fight - Law360
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback? - Yahoo Finance
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo! Finance Canada
Moderna, Inc.'s Stock Price Drops to $59.49, a Decline of 3.77%, Investors Eye Market Performance Closely - Smartkarma
Moderna says CureVac broke agreement by suing over COVID vaccine patents - Reuters
Moderna stock steadies as RSV and COVID vaccine revenues reshape outlook - AD HOC NEWS
Moderna counters CureVac patent lawsuit over Covid-19 vaccines By Investing.com - Investing.com Canada
Goldman Sachs Adjusts Moderna Price Target to $67 From $49, Maintains Neutral Rating - marketscreener.com
Wolfe Research raises Moderna stock price target to $25 on updates - Investing.com
D.A. Davidson & CO. Decreases Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Encyclopedia Britannica
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
Moderna Inc (MRNA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bancel Stephane | Chief Executive Officer |
Aug 06 '26 |
Option Exercise |
19.15 |
252,469 |
4,834,781 |
6,440,260 |
| Bancel Stephane | Chief Executive Officer |
Aug 05 '26 |
Sale |
57.52 |
499,246 |
28,715,011 |
6,187,791 |
0.79%
0.17%
大文字化:
|
ボリューム (24 時間):